8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 1, 2014

 

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-26642   87-0494517

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 7.01 Regulation FD Disclosure.

On April 1, 2014, the Centers for Medicare & Medicaid Services (CMS) provided new, updated pricing for the sequencing of the BRCA1 and BRCA2 genes. The new pricing resulted in a total reimbursement amount for Myriad’s integrated BRACAnalysis® of $2,767. Below is a summary of the change in pricing for the relevant codes:

 

Description and

CPT Code

    Previous FY14
CMS Pricing		    New FY14
CMS Pricing		    Percent
Change

BRCA 1&2 seq & com
dup/del (81211)
BRACAnalysis

    $1,438    $2,184    52%

BRCA 1&2 uncom
dup/del var (81213)
BART®

    $583    $583    No Change
  

 

   

 

   

Integrated
BRACAnalysis

    $2,021    $2,767    37%

The new reimbursement amounts will take effect for tests ordered on or after April 1, 2014.

 

Page 2 of 3 pages

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MYRIAD GENETICS, INC.
Date: April 1, 2014   By:  

/s/ Peter D. Meldrum

    Peter D. Meldrum
    President and Chief Executive Officer

 

Page 3 of 3 pages